Glucose-6-phosphate dehydrogenase deficiency.
Glucose-6-phosphate dehydrogenase (G6PD) is expressed in all tissues, where it catalyses the first step in the pentose phosphate pathway. G6PD deficiency is prevalent throughout tropical and subtropical regions of the world because of the protection it affords during malaria infection. Although most affected individuals are asymptomatic, there is a risk of neonatal jaundice and acute haemolytic anaemia, triggered by infection and the ingestion of certain drugs and broad beans (favism). A rare but more severe form of G6PD deficiency is found throughout the world and is associated with chronic non-spherocytic haemolytic anaemia. Many deficient variants of G6PD have been described. DNA sequence analysis has shown that the vast majority of these are caused by single amino acid substitutions. The three-dimensional structure of G6PD shows a classical dinucleotide binding domain and a novel beta + alpha domain involved in dimerization.
Mehta
A
A
Department of Haematology, Royal Free Hospital, London, UK.
Mason
P J
PJ
Vulliamy
T J
TJ
D000746:Anemia, Hemolytic, Congenital Nonspherocytic / Q000201:enzymology / Q000517:prevention & control / Q000628:therapy; D005954:Glucosephosphate Dehydrogenase / Q000737:chemistry / Q000235:genetics / Q000502:physiology; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000175:diagnosis / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000201:enzymology; D008288:Malaria / Q000201:enzymology / Q000517:prevention & control; D008958:Models, Molecular
D005954:Glucosephosphate Dehydrogenase